Moderna said on Monday its experimental influenza vaccine showed superior efficacy compared with a licensed standard-dose ...

Moderna's flu vaccine candidate, mRNA-1010, shows 26.6% efficacy in a Phase 3 trial for adults 50+. Read more here.

RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...

A new slate of vaccine advisers to the US Centers for Disease Control and Prevention voted Thursday to recommend that ...

The Cambridge biotech believes packaging the two immunizations together will lead to higher uptake of COVID vaccines.

CDC advisory committee recommends thimerosal-free influenza vaccines for all adults and children, despite claims that the ...

A long-lasting formulation of an antiviral drug greatly reduced people’s risk of a symptomatic flu infection in a trial, and ...

The votes on vaccine recommendations are the first move by the panel after Health and Human Services Secretary Robert F.

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

Seasonal flu-related hospitalizations and outpatient visits reached a 15-year high during the 2024-25 season, according to ...

Moderna’s mRNA flu shot outperforms existing vaccines in Phase 3 trial, showing over 26% greater efficacy—paving the way for ...

A recombinant flu vaccine (Flublok) contains no eggs and was recently approved for use in individuals aged 9 years or older ...